IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic cancer vaccines. Its lead product candidate, Cylembio (imsapepimut and etimupepimut, adjuvanted), formerly known as IO102-IO103, is an investigational therapeutic cancer vaccine. The company also has additional candidates including IO112 and IO170 in clinical or preclinical development. IO Biotech relies on third-party CMOs for manufacturing and CROs for clinical trial conduct.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-31 | 2024-12-31 | 0000950170-25-047744 | EDGAR | 114K words |
| 2024-03-05 | 2023-12-31 | 0000950170-24-026275 | EDGAR | 111K words |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007902 | EDGAR | 114K words |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005244 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-281820 | EDGAR | 76K words |
| 2025-08-14 | 2025-06-30 | 0001193125-25-180860 | EDGAR | 75K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-070956 | EDGAR | 70K words |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125524 | EDGAR | 67K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096168 | EDGAR | 68K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059108 | EDGAR | 67K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-062963 | EDGAR | 26K words |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041620 | EDGAR | 24K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021288 | EDGAR | 21K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023876 | EDGAR | 24K words |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016919 | EDGAR | 23K words |
| 2022-05-16 | 2022-03-31 | 0000950170-22-010101 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-31 | 0001193125-26-133331 | EDGAR | 1K words |
| 2026-02-13 | 0001193125-26-051790 | EDGAR | 1K words |
| 2026-01-30 | 0001193125-26-031987 | EDGAR | 0K words |
| 2026-01-21 | 0001193125-26-017164 | EDGAR | 0K words |
| 2025-12-19 | 0001193125-25-327089 | EDGAR | 1K words |
| 2025-11-21 | 0001193125-25-291504 | EDGAR | 1K words |
| 2025-11-18 | 0001193125-25-285282 | EDGAR | 4K words |
| 2025-11-14 | 0001193125-25-281657 | EDGAR | 4K words |
| 2025-09-29 | 0001193125-25-221704 | EDGAR | 1K words |
| 2025-08-14 | 0001193125-25-180830 | EDGAR | 4K words |
83 total filings indexed. 57 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001865494 |
| Ticker | IOBT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IOBT (~200 tokens, structured JSON with cryptographic provenance)